Cormorant Asset Management, LP, 10% Owner at Ambrx Biopharma, Inc. (AMAM), bought 2,614,622 shares at $6.99 ($18.3M) on 2023-10-23, disclosed to the SEC on 2023-10-25.
Open-market purchase of $18.3M AMAM by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.99 | 1,307,311 | $9.1M | 50.0% |
| 2 | $6.99 | 1,307,311 | $9.1M | 50.0% |
| Total | $6.99 avg | 2,614,622 | $18.3M | 100% |
| Filing → |
| DRUG | BUY | 2024-11-06 | $8.0M | — | Filing → |
| EYPT | BUY | 2024-05-08 | $20.2M | — | Filing → |
| CRBP | BUY | 2024-02-06 | $14.3M | — | Filing → |